Chronic Kidney Disease and Cognitive Function in Older Adults: Findings from the Chronic Renal Insufficiency Cohort Cognitive Study

Kristine Yaffe, MD, Lynn Ackerson, PhD, Manjula Kurella Tamura, MD, MPH, Patti Le Blanc, MA, John W. Kusek, PhD, Ashwini R. Sehgal, MD, Debbie Cohen, MD, Cheryl Anderson, PhD, Lawrence Appel, MD, Karen DeSalvo, MD, MPH, Akinlolu Ojo, MD, PhD, Stephen Seliger, MD, Nancy Robinson, MD, Gail Makos, RN, MSN, and Alan S. Go, MD, for the Chronic Renal Insufficiency Cohort Investigators

OBJECTIVES: To investigate cognitive impairment in older, ethnically diverse individuals with a broad range of kidney function, to evaluate a spectrum of cognitive domains, and to determine whether the relationship between chronic kidney disease (CKD) and cognitive function is independent of demographic and clinical factors.

DESIGN: Cross-sectional.

SETTING: Chronic Renal Insufficiency Cohort Study.

PARTICIPANTS: Eight hundred twenty-five adults aged 55 and older with CKD.

MEASUREMENTS: Estimated glomerular filtration rate (eGFR, mL/min per 1.73 m²) was estimated using the four-variable Modification of Diet in Renal Disease equation. Cognitive scores on six cognitive tests were compared across eGFR strata using linear regression; multivariable logistic regression was used to examine level of CKD and clinically significant cognitive impairment (score ≤1 standard deviations from the mean).

RESULTS: Mean age of the participants was 64.9, 50.4% were male, and 44.5% were black. After multivariable adjustment, participants with lower eGFR had lower cognitive scores on most cognitive domains (P<.05). In addition, participants with advanced CKD (eGFR <30) were more likely to have clinically significant cognitive impairment on global cognition (adjusted odds ratio (AOR) 2.0, 95% CI = 1.1–3.9), naming (AOR = 1.9, 95% CI = 1.0–3.9), attention (AOR = 2.4, 95% CI = 1.3–4.5), executive function (AOR = 2.5, 95% CI = 1.9–4.4), and delayed memory (AOR = 1.5, 95% CI = 0.9–2.6) but not on category fluency (AOR = 1.1, 95% CI = 0.6–2.0) than those with mild to moderate CKD (eGFR 45–59).

CONCLUSION: In older adults with CKD, lower level of kidney function was associated with lower cognitive function on most domains. These results suggest that older patients with advanced CKD should be screened for cognitive impairment.


Key words: chronic kidney disease; cognitive impairment; cognitive function

The prevalence of chronic kidney disease (CKD) increases with advancing age. Similarly, cognitive impairment is more common in older adults. Both conditions are associated with greater healthcare use and poorer quality of life and are of increasing public health significance. Whether CKD is associated with accelerated cognitive aging has not been rigorously addressed. There are several potential mechanisms, including cerebrovascular disease, metabolic...
dysregulation,6 and direct effects of kidney disease7–9 that may link CKD with impaired cognitive function.

The few studies that have investigated the association between CKD before kidney failure and cognitive outcomes suggest that older adults with very low levels of kidney function have worse cognitive function than those without CKD,10–14 but little is known about the specific cognitive domains affected in CKD, because most of the prior research studies have used global cognitive screening measures rather than tests of specific domains. In addition, they had limited representation of minority subjects and a limited range of kidney function.

The Chronic Renal Insufficiency Cohort (CRIC) Study, a prospective observational cohort study, was established to examine the risk factors and mechanisms of progression of CKD and cardiovascular disease (CVD). The CRIC Cognitive (CRIC COG) Study, an ancillary study to CRIC, provided the opportunity to investigate cognitive impairment in older, ethnically diverse individuals with a broad range of kidney function, to evaluate a spectrum of cognitive domains, and to determine whether the relationship between CKD and cognitive function is independent of demographic and clinical factors.

METHODS

Study Design

The CRIC Study is a prospective cohort study designed to evaluate the risk factors and mechanisms of progression of CKD and CVD in adults with mild to moderate CKD. A total of 3,612 participants (47.0% with diabetes mellitus (DM)) were enrolled at seven clinical centers from May 2003 to March 2007 and are being followed annually until death or withdrawal of informed consent. The study design and methods have been published previously.15

The present study of cognitive function, called the CRIC COG Study, is ancillary to the parent CRIC Study. Similar to its parent study, the CRIC COG is a prospective observational cohort study that recruited study participants from four of the seven clinical CRIC centers located in Philadelphia, Pennsylvania; Cleveland, Ohio; Oakland, California; and Chicago, Illinois. Only persons enrolled in the CRIC Study and who were aged 55 and older were eligible for the cognitive function study. At their next scheduled in-clinic visit, eligible participants were enrolled in the CRIC COG Study and administered a cognitive battery. This served as the baseline visit for the study but may not have coincided with the baseline visit for the parent study. Thus “baseline” in this report is the participants’ first visit as part of CRIC COG Study.

Institutional review boards at each of the participating sites and at the University of California at San Francisco approved the CRIC COG Study, and all participants gave written informed consent.

Study Population

To be enrolled in the CRIC Study, participants must be aged 21 to 74 and have an estimated glomerular filtration rate (eGFR) of 20 to 70 mL/min per 1.73 m² if aged 21 to 44, 20 to 60 mL/min per 1.73 m² if aged 45 to 64, and 20 to 50 mL/min per 1.73 m² if aged 65 to 74. They were not eligible if they were institutionalized, did not provide informed consent, had previously undergone dialysis for longer than 1 month, were diagnosed with polycystic kidney disease, had received a prior organ or bone marrow transplant, were taking immunosuppressive drugs for kidney disease in the past 6 months, or were currently participating in a clinical trial or the African American Study of Kidney Disease and Hypertension, an ongoing cohort study at some of the centers. Other exclusions included New York Heart Association Class III or IV heart failure, cirrhosis, human immunodeficiency virus infection or acquired immunodeficiency syndrome, chemotherapy for cancer within 2 years, multiple myeloma, or renal cell carcinoma.15 The CRIC COG Study required that participants be enrolled in the CRIC Study and be aged 55 and older. This minimum age requirement was established to increase the likelihood of observing clinically significant cognitive decline in the sample. The target sample size was 720, with equal recruitment from the four clinical centers.

Predictor Variable

The primary predictor of interest was level of kidney function. eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) estimating equation.16 Whenever possible, the eGFR value determined at the CRIC visit coinciding with the CRIC COG baseline visit was used. In cases (n = 8; 0.9%) in which visits did not coincide or when eGFR was missing, the most recent eGFR value was used (mean interval of 1.4 years).

Cognitive Function Measures

Six cognitive function tests (with 7 scores) were administered in the CRIC COG Study: the Modified Mini-Mental State Examination (3MS), the Trail Making Test Parts A and B (Trails A and B), Category (verbal) Fluency, Buschke Selective Reminding Test (immediate and delayed memory), and Boston Naming. The 3MS is a brief, general cognitive battery with components for orientation, concentration, language, praxis, and immediate and delayed memory, with scores ranging from 0 to 100, higher scores indicating better function.17 Trails A and B measure visuospatial scanning, motor speed, executive function, and attention.18 Trails B is primarily a test of executive function, and Trails A is predominantly a test of attention. The scores are based on the time to complete a particular task, and therefore, lower scores indicate higher function. Category (verbal) Fluency measures verbal production, semantic memory, and language, with higher scores indicating better performance.19 Category Fluency and Trails B are typically impaired in the context of subcortical vascular disease.20 The Buschke Selective Reminding Test is a well-established test of verbal memory, with immediate and delayed components.21 Verbal memory is one of the earliest cognitive domains to be affected in Alzheimer's disease (AD) and is a hallmark feature of all dementias.22 Higher scores indicate higher function. The Modified Boston Naming test is a 15-item test of language function that requires the participant to name objects presented in pictures.19 Language deficits, such as those found with naming, are a hallmark feature of early AD. Higher scores indicate higher function.
Clinically significant impairment was defined as having a score 1 standard deviation (SD) below the mean or lower, except for the Trails A and B, in which case impairment was a score at least 1 SD above the mean.

**Covariates**

Covariates included additional data collected as part of the CRIC Study, including sociodemographic characteristics, relevant medical history (diabetes mellitus, diagnosed hypertension; self-reported at each annual clinic visit if a doctor told them they had that condition), body mass index (BMI; measured as weight (kg) divided by the square of height (m)), and resting blood pressure (systolic and diastolic; mean of three seated measurements, 30 seconds apart), each measured or updated annually. The Beck Depression Inventory (BDI) was collected biannually and moderate to severe depression was defined as a score greater than 14.23

**Statistical Methods**

Baseline characteristics were compared across eGFR categories (≥60, 45–59, 30–44, and <30 mL/min per 1.73 m²) using analysis of variance for normally distributed continuous data, Kruskal-Wallis test for nonnormally distributed continuous data, and chi-square tests for categorical data. Tests for trend were performed using the Cochran-Armitage Trend Test on categorical variables and orthogonal polynomial contrasts within the general linear models for continuous variables. The outcome variables of interest are the six cognitive function tests, resulting in seven scores. The primary analysis was a comparison of each score across category of eGFR level using a linear regression model, so an association between kidney function and cognitive function could be tested for. Adjustment was made for the following possible confounding variables based on their association (P < .10) with CKD and cognitive function: age, education, sex, BMI, diabetes mellitus, hypertension, and depression. Additionally, adjustment was made for race based on prior published studies showing separate associations between race and CKD9,10 and between race and cognitive function.24,25

Differences in likelihood of clinically significant cognitive impairment were further tested for across eGFR strata using logistic regression models, with adjustment for age, race, education, sex, BMI, diabetes mellitus, hypertension, and depression score. For these analyses, the reference group was the subgroup of participants with eGFR of 45 to 59 mL/min per 1.73 m². (The 80 participants with eGFR <60 mL/min per 1.73 m² were not chosen to be the reference, because they had demonstrated lower levels of kidney function at the time of screening several months before and did not seem to appropriately represent older adults with eGFR ≥60.) Results are summarized with odds ratios (ORs) and 95% confidence intervals (CIs). Models were run with and without adjustment for possible confounders. All analyses were done using SAS version 9.1 (SAS Institute, Inc., Cary, NC).

**RESULTS**

A total of 825 participants were recruited into the CRIC COG Study (of those who were eligible; 983 were asked to participate). This cohort had a mean age ± SD of 64.9 ± 5.6 and was 50.4% male and 44.5% black. Site enrollment included 205 participants from the University of Pennsylvania center, 223 participants from the Case Western Reserve center, 196 from the University of Illinois at Chicago center, and 201 from the Kaiser Permanente of Northern California/University of California San Francisco center. At the time of cognitive testing, mean eGFR was 41.0 ± 14.3 mL/min per 1.73 m², with 80 participants having an eGFR of 60 mL/min per 1.73 m² or greater (mean 61 mL/min per 1.73 m²), 289 with an eGFR of 45 to 59 mL/min per 1.73 m² (mean 49 mL/min per 1.73 m²), 299 with an eGFR of 30 to 44 mL/min per 1.73 m² (mean 37 mL/min per 1.73 m²), and 157 with an eGFR of less than 30 (mean 24 mL/min per 1.73 m²). The characteristics of the CRIC COG participants were compared across eGFR categories (Table 1). Participants with lower eGFR tended to be older and have less educational attainment and greater comorbidity burden, including diabetes mellitus and hypertension.

In unadjusted analyses, for each of the cognitive tests, a consistent pattern of worse cognitive scores in participants with greater CKD severity was observed. For example, for the 3MS, participants with an eGFR of 60 mL/min per 1.73 m² or greater had a mean score of 95.2 ± 5.0, those with an eGFR of 45 to 59 mL/min per 1.73 m² had a score of 94.0 ± 7.6, those with an eGFR of 30 to 44 mL/min per 1.73 m² had a score of 92.1 ± 7.1, and those with an eGFR less than 30 mL/min per 1.73 m² had a score of 91.4 ± 7.8 (P < .001 for trend). For the Trails B test, mean scores were 115.7 ± 70.3, 126.1 ± 70.1, 150.9 ± 83.0, and 163.9 ± 85.1, respectively (P < .001 for trend). A similar pattern emerged for the other four cognitive tests (5 subscores). Multivariable adjustment for age, sex, race, education, BMI, diabetes mellitus, hypertension, and depression did not alter the findings, with the exception of the Category Fluency and Buschke tests (Table 2).

The association between severity of CKD and clinically significant cognitive impairment, defined as a score 1 SD or more more severe from the mean, was next determined (Table 3). Participants with more-severe CKD had higher prevalence of cognitive impairment on global cognition (21.7% for eGFR <30 mL/min per 1.73 m², 14.1% for eGFR 30–44 mL/min per 1.73 m², 9.7% for eGFR 45–59 mL/min per 1.73 m², 5.0% for eGFR ≥60 mL/min per 1.73 m², P < .001 for trend), attention (20.4%, 16.5%, 8.7%, 3.8%, respectively, P < .001), executive function (28.0%, 23.2%, 12.2%, 11.3%, respectively, P < .001), naming (23.6%, 20.1%, 12.5%, 7.5%, respectively, P < .001), category fluency (16.6%, 15.2%, 12.5%, 5.0%, respectively, P = .02), and delayed memory (19.1%, 17.4%, 13.3%, 5.0%, respectively, P = .003). Although this pattern was also evident for the test of immediate memory (22.3%, 22.1%, 17.0%, 18.8%, respectively, P = .16), the differences were not statistically significant. After multivariable adjustment for age, sex, race, education, hypertension, depression, BMI, and diabetes mellitus, participants with more-severe CKD continued to demonstrate greater likelihood of cognitive impairment on most tests (Figure 1). Participants with advanced CKD (eGFR <30) were more likely to have cognitive impairment on tests of global cognition (adjusted odds ratio (AOR) = 2.0, 95% CI = 1.1–3.9), naming (AOR = 1.9, 95% CI = 1.0–3.3), attention (AOR = 2.4, 95% CI = 1.3–4.5), executive function (AOR = 2.5, 95% CI = 1.9–4.4) and delayed
memory (AOR = 1.5, 95% CI = 0.9–2.6) but not on category fluency (AOR = 1.1, 95% CI = 0.6–2.0) or immediate memory (AOR = 1.2, 95% CI = 0.7–2.1) than those with mild or moderate CKD (eGFR 45–59).

In subgroup analyses defined a priori according to a diagnosis of diabetes mellitus, race (black vs white) and sex, consistent interactions for these strata ($P > .10$ for all) and the association between level of eGFR and cognitive function were not observed. The cohort was also stratified according to age (55–64, 65–74, and ≥75), and it was found that the prevalence of global cognitive impairment (defined according to the 3MS) was 9.1%, 18.4%, and 13.3%, respectively, but there was no interaction according to age on the association between CKD severity and cognitive function.

**DISCUSSION**
In the CRIC COG Study, it was found that baseline cognitive function measured across multiple domains was worse in participants with more-severe kidney disease, even after adjustment for several potential confounders, including demographic characteristics and relevant comorbidities. The proportion of participants with clinically meaningful cognitive impairment was much greater for those with

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>≥60 (n = 80)</th>
<th>45–59 (n = 289)</th>
<th>30–44 (n = 299)</th>
<th>&lt;30 (n = 157)</th>
<th>P-Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean ± SD</td>
<td>61.5 ± 3.5</td>
<td>64.8 ± 5.6</td>
<td>65.5 ± 5.7</td>
<td>65.6 ± 5.7</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>44 (55.0)</td>
<td>162 (56.1)</td>
<td>139 (46.5)</td>
<td>71 (45.2)</td>
<td>0.05</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.70</td>
</tr>
<tr>
<td>White</td>
<td>42 (52.5)</td>
<td>144 (49.8)</td>
<td>145 (48.5)</td>
<td>70 (44.6)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>33 (41.3)</td>
<td>120 (41.5)</td>
<td>138 (46.2)</td>
<td>76 (48.4)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>5 (6.3)</td>
<td>20 (6.9)</td>
<td>14 (4.7)</td>
<td>11 (7.0)</td>
<td></td>
</tr>
<tr>
<td>Hispanic ethnicity</td>
<td>2 (2.5)</td>
<td>11 (3.8)</td>
<td>6 (2.0)</td>
<td>3 (1.9)</td>
<td>0.51</td>
</tr>
<tr>
<td>Education &lt;high school, n (%)</td>
<td>22 (27.5)</td>
<td>82 (28.4)</td>
<td>124 (41.5)</td>
<td>67 (42.7)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Married or domestic partner, n (%)</td>
<td>50 (62.5)</td>
<td>165 (57.1)</td>
<td>151 (50.5)</td>
<td>83 (52.9)</td>
<td>0.18</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>32 (40.0)</td>
<td>125 (43.3)</td>
<td>176 (58.9)</td>
<td>88 (56.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Current smoker, n (%)</td>
<td>10 (12.5)</td>
<td>27 (9.3)</td>
<td>40 (13.4)</td>
<td>14 (8.9)</td>
<td>0.33</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>62 (77.5)</td>
<td>251 (86.9)</td>
<td>289 (96.7)</td>
<td>150 (95.5)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Stroke, n (%)</td>
<td>5 (6.3)</td>
<td>30 (10.4)</td>
<td>37 (12.4)</td>
<td>20 (13.4)</td>
<td>0.40</td>
</tr>
<tr>
<td>Depression, n (%)</td>
<td>13 (16.3)</td>
<td>31 (10.7)</td>
<td>59 (19.7)</td>
<td>21 (13.4)</td>
<td>0.02</td>
</tr>
<tr>
<td>Body mass index, kg/m², mean ± SD</td>
<td>31.0 ± 5.9</td>
<td>31.3 ± 7.8</td>
<td>32.9 ± 7.8</td>
<td>32.1 ± 8.5</td>
<td>0.06</td>
</tr>
<tr>
<td>Systolic blood pressure, mean ± SD</td>
<td>119.3 ± 14.3</td>
<td>126.5 ± 21.2</td>
<td>129.9 ± 24.2</td>
<td>130.9 ± 22.3</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Diastolic blood pressure, mean ± SD</td>
<td>68.7 ± 11.8</td>
<td>67.6 ± 12.2</td>
<td>67.1 ± 12.5</td>
<td>65.7 ± 11.5</td>
<td>&lt;.028</td>
</tr>
</tbody>
</table>

*P-value is for test of differences across levels of estimated glomerular filtration rate (eGFR). SD = standard deviation.

There were no interactions by age. The mean cognitive function score was worse in participants with more-severe kidney disease, even after adjustment for several potential confounders, including demographic characteristics and relevant comorbidities. The proportion of participants with clinically meaningful cognitive impairment was much greater for those with moderate or severe CKD (eGFR 30–44) than those with mild or moderate CKD (eGFR 45–59).

In subgroup analyses defined a priori according to a diagnosis of diabetes mellitus, race (black vs white) and sex, consistent interactions for these strata ($P > .10$ for all) and the association between level of eGFR and cognitive function were not observed. The cohort was also stratified according to age (55–64, 65–74, and ≥75), and it was found that the prevalence of global cognitive impairment (defined according to the 3MS) was 9.1%, 18.4%, and 13.3%, respectively, but there was no interaction according to age on the association between CKD severity and cognitive function.

**DISCUSSION**
In the CRIC COG Study, it was found that baseline cognitive function measured across multiple domains was worse in participants with more-severe kidney disease, even after adjustment for several potential confounders, including demographic characteristics and relevant comorbidities. The proportion of participants with clinically meaningful cognitive impairment was much greater for those with

<table>
<thead>
<tr>
<th>Cognitive Test</th>
<th>N</th>
<th>≥60 (mL/min per 1.73m²) Mean (Standard Error)</th>
<th>45–59</th>
<th>30–44</th>
<th>&lt;30</th>
<th>P-Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modified Mini-Mental State Examination (range 0–100)</td>
<td>813</td>
<td>92.8 (0.82)</td>
<td>92.2 (0.61)</td>
<td>91.2 (0.62)</td>
<td>91.0 (0.70)</td>
<td>.01</td>
</tr>
<tr>
<td>Trail Making Test (range 0–300)</td>
<td>810</td>
<td>49.3 (4.44)</td>
<td>53.7 (3.30)</td>
<td>62.9 (3.37)</td>
<td>68.0 (3.77)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Boston Naming (range 0–15)</td>
<td>811</td>
<td>13.6 (0.18)</td>
<td>13.5 (0.11)</td>
<td>13.3 (0.11)</td>
<td>13.2 (0.13)</td>
<td>0.02</td>
</tr>
<tr>
<td>Category Fluency (range 0–45)</td>
<td>811</td>
<td>17.7 (0.61)</td>
<td>16.4 (0.46)</td>
<td>16.5 (0.46)</td>
<td>16.6 (0.52)</td>
<td>0.11</td>
</tr>
<tr>
<td>Buschke Selective Reminding Test</td>
<td>813</td>
<td>6.4 (0.24)</td>
<td>6.3 (0.18)</td>
<td>6.1 (0.18)</td>
<td>6.1 (0.20)</td>
<td>0.14</td>
</tr>
<tr>
<td>Immediate Recall (range 0–12)</td>
<td>804</td>
<td>7.9 (0.37)</td>
<td>7.4 (0.28)</td>
<td>7.4 (0.28)</td>
<td>7.3 (0.32)</td>
<td>0.12</td>
</tr>
</tbody>
</table>

Adjusted for age, race, education, sex, diabetes mellitus, hypertension, body mass index, and depression.
Higher scores indicate higher function for all tests except for Trails A and B, on which lower scores are better.
*P-value for test of trend.
more-severe CKD as well. This pattern was observed for most of the cognitive domains, including global cognition, verbal memory, attention, naming, and executive function, but not for verbal fluency. Similar findings were observed for participants with and without diabetes mellitus, men and women, and blacks and whites.

These findings support and extend the findings observed by several published cross-sectional studies. Of 1,015 postmenopausal women with CVD, for every 10 mL/min per 1.73 m$^2$ reduction in GFR, there was a 27% increase in likelihood of global cognitive impairment. In more than 20,000 U.S. adults, lower levels of kidney function were found to be associated with greater prevalence of cognitive impairment.13 Level of eGFR was associated with cognitive impairment on executive function, memory, and language measures.26 In other studies, subjects with CKD had significantly poorer performance on tests of executive function, verbal memory, and global performance.27,28 Similarly, patients with CKD performed significantly worse on executive and memory measures than controls in a small clinical sample.14 The few longitudinal studies that have been conducted on CKD and cognition also support the current study’s observations. Of more than 3,000 older adults, those with CKD (defined as an eGFR < 60 mL/min per 1.73 m$^2$) had greater 3MS score decline over 4 years than those without CKD, although there were few participants with severe CKD.15 One of the only studies to investigate the association between CKD and dementia reported a high risk of incident dementia in elderly subjects with CKD participating in the Cardiovascular Health Cognition Study,11 although another longitudinal study did not find an association between kidney function and global cognitive impairment or risk in cognitive decline.12 This may be due to differences in study populations, because that study cohort comprised older community-dwelling men primarily without CKD.12

There are several mechanisms that might link CKD with cognitive impairment. Individuals with CKD have a greater prevalence of established CVD and cardiovascular risk factors, and these same risk factors increase the risk of developing dementia, including AD and vascular dementia.3 CKD is also associated with a number of other factors that also may induce cognitive impairment, including anemia, high levels of inflammatory cytokines, oxidative stress, and alterations in lipid and homocysteine metabolism.29–33

Figure 1. The likelihood of cognitive impairment (adjusted odds ratios and 95% confidence intervals) across estimated glomerular filtration rate (eGFR) category (reference group is 45–59 mL/min per 1.73 m$^2$). Models were adjusted for age, sex, race, education, diabetes, hypertension, body mass index, and depression. *P-value for trend test < .05. Modified Mini-Mental State Examination (3MS) scores range from 0 to 100; Trail Making Test Parts A and B (Trails A and B) scores range from 0 to 300; Boston Naming scores range from 0 to 15; Category Fluency scores range from 0 to 45; Buschke Immediate and Delayed Recall scores range from 0 to 12; higher scores indicate higher function for all tests except for Trails A and B in which lower scores are better.

### Table 3. Prevalence and Unadjusted Odds Ratios of Clinically Significant Cognitive Impairment, According to Estimated Glomerular Filtration Rate (eGFR) Group

<table>
<thead>
<tr>
<th>Cognitive Test</th>
<th>eGFR Rate (mL/min per 1.73 m$^2$)</th>
<th>Odds Ratio (95% Confidence Interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>≥60</td>
<td>45–59</td>
</tr>
<tr>
<td>Modified Mini-Mental State Examination</td>
<td>5.0; 0.5 (0.2–1.4)</td>
<td>9.7; Reference</td>
</tr>
<tr>
<td>Trail Making Test</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Part A</td>
<td>3.8; 0.4 (0.1–1.4)</td>
<td>8.7; Reference</td>
</tr>
<tr>
<td>Part B</td>
<td>11.3; 0.9 (0.4–2.0)</td>
<td>12.2; Reference</td>
</tr>
<tr>
<td>Boston Naming</td>
<td>7.5; 0.6 (0.2–1.4)</td>
<td>12.5; Reference</td>
</tr>
<tr>
<td>Category Fluency</td>
<td>5.0; 0.4 (0.1–1.1)</td>
<td>12.5; Reference</td>
</tr>
<tr>
<td>Buschke Selective Reminding Test</td>
<td>Immediate Recall</td>
<td>18.8; 1.1 (0.6–2.1)</td>
</tr>
<tr>
<td></td>
<td>Delayed Recall</td>
<td>5.0; 0.3 (0.1–1.0)</td>
</tr>
</tbody>
</table>

YAFFE ET AL.
cognitive function was independent of demographics and comorbidities.

Some limitations of the study deserve mention. As a cross-sectional analysis, the ability to draw causal conclusions between level of eGFR and cognitive function is limited. The pattern of cognitive deficits is more suggestive of subcortical vascular disease involvement than underlying AD, but without structural brain imaging results, the etiology of clinically significant cognitive impairment cannot be determined. Despite the large, diverse sample of patients with CKD, these results may not be fully generalizable to the broader population with CKD in the United States, and CRIC participants with an eGFR of 60 mL/min per 1.73 m² or greater most certainly are not reflective of people with better kidney function, because they at one time had an eGFR less than 60 mL/min per 1.73 m². Finally, although the effect sizes may seem small for some of the cognitive tests (e.g., 3MS), similar effect sizes have been found in studies investigating better-studied risk factors for cognitive impairment, such as hypertension or dyslipidemia.34,35

In this summary, this study found that lower levels of eGFR were independently associated with impaired cognitive functioning across multiple different domains, especially related to tests of executive function, even after adjustment for sociodemographic and clinical factors. These results suggest that screening older patients with advanced CKD for cognitive impairment might be important, but future research is needed to determine the appropriate screening tools and the sensitivity and specificity of various cut-points for screening. It is hoped that the ongoing longitudinal assessments of the CRIC COG Study will facilitate better understanding of the clinical importance, etiology, and mechanisms explaining the association between CKD severity and cognition.

ACKNOWLEDGMENTS
Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper. This study was funded by National Institute of Health Grants U01-DK060990, U01 DK06980, U01 DK 60902, U01 DK61021, U01 DK60984, and R01 DK069406 (CRIC COG). Dr. Yaffe is also supported in part by K24 AG 031155 and an anonymous foundation.

Author Contributions: Study concept and design: KY, MKT, JWK, ASG. Acquisition of subjects and data analysis: KY, ASG. Interpretation of data: KY, LA, MKT, JWK, ARS, ASG. Preparation of manuscript: KY, PLB, JWK, ARS, DC, CA, LA, KD, AO, SS, NR, GM.
Sponsor’s Role: None.

REFERENCES

Appendix A. Chronic Renal Insufficiency Cohort (CRIC) Study

University of Pennsylvania Scientific & Data Coordinating Center
Harold I. Feldman, MD, MSCE (PI)
J. Richard Landis, PhD
Shawn Ballard, MS
Zhen Chen, PhD
Denise Citelli
Robert M. Curley, MS
James Dattilo
Marie Durborow
Stephen Durborow
Susan Echus, PhD
Jamison Fargo, PhD
Melanie Glenn, MPH
Asaf Hanish, MPH
Christopher Helker, MSPH
Maximilian Herlim
Amanda Hyre Anderson, PhD, MPH
J. Sanford Schwartz, MD
Raymond R. Townsend, MD (PI)

University of Pennsylvania Medical Center
Raymond R. Townsend, MD (PI)
*Thomas Capolla, MD, ScM
Debbie Cohen, MD
Magdalena Cuevas
Mark J. Duckworth
Virginia Ford, MSN, CRNP
Colin M. Gorman
*Juan Grunwald, MD
Lucy Kibe, MS
*Mary B. Leonard, MD, MSCE
*Maureen Maguire, PhD
Stephanie McDowell
John Murphy, MD
*Muredach Reilly, MB
*Sylvia E. Rosas, MD
Wanda M. Seamon
Angie Sheridan, MPH
Karen Teff, MD

The Johns Hopkins University
Lawrence J. Appel, MD, MPH (PI)
Cheryl Anderson, PhD, MPH
Brad Astor, PhD, MPH
Jeanne Charleston, RN
Bernard Jaar, MD, MPH
Edgar “Pete” Miller, MD

University of Maryland
Jeffrey Fink, MD, MS (Co-PI)
Wanda Fink, RN, BSN
Afshin Parsa, MD, MPH
Beth Scism
Stephen Seliger, MD, MS
Matthew Weir, MD

University Hospitals of Cleveland Case Medical Center
Mahboob Rahman, MD (PI)
Renita Brooks
Valori Corrigan RN
Genya Kin MS
Rahida Kanthety
Louise Strauss, RN
Jackson T. Wright, Jr., MD, PhD

MetroHealth Medical Center
Jeffrey Schelling, MD (PI)
Patricia Kao, MD (Co-PI)
Ed Horowitz, MD (Co-PI)
Jacqui Bjelovcik
Theresa Falloon
John R. Sedor, MD
Mary Ann Sheila, RN, BSN
Jacqueline Theurer
J. Daryl Thornton, MD, MPH

Cleveland Clinical Foundation
Martin J. Schreiber, MD (Co-PI)
Martha Coleman, RN
Richard Fatica, MD
David Frey
Darla Greenwald
Sandra Halliburton, PhD
Carol Horner, BSN, RN
Teresa Markle, BS
Sandra Pangonis, RN
Carmen Paradis, MD
Mohammed A. Rafey, MD, MS
Annette Russo
Stephanie Slattery, RN
Jackie Soos
Rita Spirko, RN, MSN
Kay Stelmach, RN
Velma Stephens, LPN

University of Michigan at Ann Arbor
Akinlolu Ojo, MD, PhD (PI)
Anil Attili, MD
Jeff Briesmiester
Tonya L. Corbin, MD
Denise Cornish-Zikrle, BSN
Crystal Gadgebuku, MD
Nancy Hill
Kenneth Jamerson, MD
Bruce Robinson, MD
Rajiv Saran, MD
Bonnie Welliver, BSN, CNN
Jillian Wilson
Eric Young, MD, MS

St. John’s Health System
Susan P. Steigerwalt, MD, FACP (Co-PI)
Keith Bellovich, DO
Jennifer DeLuca
Sherry Gasko, BSN
Gail Makos, RN, MSN
Chantal Parmelee
Shahan Smith
Kathleen Walls

Wayne State University
John M. Flack, MD, MPh (Co-PI)
Andrew Johnson III, RN
Mary Maysura
Barbara Lloyd, MA, RD
Stephen Migdal, MD
M. Jena Mohanty, MD
Yanni Zhuang, BSN

University of Illinois at Chicago
James P. Lash, MD (PI)
Jose Arruda, MD
Carolyn Brecklin, MD
Eunice Carmona, BA
Janet Cohan, MSN
Michael Fischer, MD, MSPH
Leon Fogelfeld
Anne Frydrych, MS, RD
Amada Lopez
*Claudia Lora, MD
Monica Martinez
Alejandro Mercado, BA
Patricia Meslar, MSN
Kalyani Perumal, MD
Iris Sanchez, BA
Thomas Stamos, MD
*Eve Van Cauter, PhD

Tulane University Health Science Center
Jiang He, MD, PhD (PI)
Brent Alper, MD
Vecchi Batuman, M.D
Lydia A. Bazzano, MD, PhD
Bernadette Borja
Adriana Berridge
Jing Chen, MD, MSPH
Catherine Cooke
Patrice Delafoante, MD
Karen B. DeSalvo, MD, MPH, MSPH
Vivian A. Fonseca, MD
Lee Hamm, MD
Michelle R. Hurley, RN, BSN
Eva Lustigova, MPH
*Paul Muntner, PhD
Lindsey Powers
Paul Whelton, MD, MSc

Kaiser Permanente of Northern California

Alan S. Go, MD (PI)
Lynn M. Ackerson, PhD
Pete Dorin, MPA
Daniel Fernandez
Rosi Fox
Nancy G. Jensvold, MPH
Joan C. Lo, MD
Juan D. Ordonez, MD, MPH
Rachel Perloff
Thida Tan, MPH
Daphne Thompson
Gina M. Valladares
Annette Wiggins, RN
Diana B. Wong, RN, MPH
Jingrong (Michelle) Yang, MA

University of California, San Francisco

Chi-yuan Hsu, MD, MSc (Co-PI)
Glenn M. Chertow, MD, MPH
Nisha Bansal, MD
Irina Gorodetskaya
*Dominic Raj MD, DM
*Vallabh Shah, PhD

Consultants- Harvard School of Med

Paul M. Ridker, MD

Central Lab-University of Pennsylvania

Daniel J. Rader, MD
Anna DiFlorio
Ted Mifflin
Linda Morrell
Megan L. Wolfe

GFR Lab-Cleveland Clinic

Phillip Hall, MD
Sue Saunders

EBT Reading Center- UCLA

Mathew Budoff, MD
Chris Dailing

ECG Reading Center- Wake Forest

Ronald Prineas, MD, PhD
Elsayed Soliman, MD
Zhu-Ming Zhang, MD

Kaiser NIH/NCRR UCSF-CTSI

Echo Reading Center- University of Pennsylvania
Martin St. John Sutton, MBBS
Martin G. Keane, MD, FACC, FAHA

University of Pennsylvania CTRC CTSA
UL1 RR-024134

The Johns Hopkins University
UL1 RR-025005

University of Maryland GCRC
M01 RR-16500

Case Western Reserve University Clinical and Translational Science Collaborative (University Hospitals of Cleveland, Cleveland Clinic Foundation, and MetroHealth)
UL1 RR-024989

University of Michigan
GCRC grant number M01 RR-000042
CTSA grant number UL1 RR-024986

University of Illinois at Chicago CTSA
UL1RR029879

Tulane/LSU/Charity Hospital General Clinical Research Center
RR-05096

Kaiser NIH/NCRR UCSF-CTSI
UL1 RR-024131

*Ancillary Investigator